AccessMyLibrary provides FREE access to over 30 million articles from top publications available through your library.
Create a link to this page
Copy and paste this link tag into your Web page or blog:
2003 OCT 1 - (NewsRx.com & NewsRx.net) -- Cangene has entered a collaborative research and development agreement with Acambis plc to develop and manufacture a hyperimmune globulin for treating and preventing infection by West Nile virus (West Nile Immune Globulin; WNIG).
The companies will share development and funding for the project. Acambis will provide its investigational ChimeriVax-West Nile vaccine, qualified product-assay technology, and testing for efficacy of the WNIG. Cangene will collect plasma and develop and manufacture the product using its established manufacturing process in its Winnipeg facility.
A hyperimmune globulin against West Nile may be used to treat people who have become infected with the virus and to give immediate protection to immunocompromised individuals, such as the elderly, whose immune systems may not be able to generate a sufficient immune response.
"West Nile spread across North America at an astonishing rate and has rapidly established itself as a public health concern. With operations in Manitoba and Ontario we are acutely aware of the threat of mosquito-borne infections and we believe that hyperimmune technology is well suited to meet the challenge," said John Langstaff, president and CEO of Cangene Corporation.
West Nile virus is a flavivirus spread by mosquitoes that have fed on the blood of infected birds. West Nile virus is closely related to the viruses that cause dengue fever, yellow fever, and St. Louis encephalitis. The first recorded outbreak in North America occurred in New York City in 1999. In Canada, the virus was first confirmed in birds ...
Source: HighBeam Research, Deal signed to share development of West Nile virus hyperimmune...